BCTXZ

BriaCell Therapeutics Corp. Warrant

0.1900 USD
-0.0200
9.52%
At close Updated Sep 16, 4:00 PM EDT
1 day
-9.52%
5 days
-9.52%
1 month
-26.89%
3 months
-81.37%
6 months
-85.5%
Year to date
-85.5%
1 year
-85.5%
5 years
-85.5%
10 years
-85.5%
 

About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Employees: 12

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

49.42% more ownership

Funds ownership: 0% [Q1] → 49.42% (+49.42%) [Q2]

Financial journalist opinion

We haven’t received any recent news articles for BCTXZ

Charts implemented using Lightweight Charts™